IMR Press / FBL / Volume 18 / Issue 2 / DOI: 10.2741/4117

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Review
TGM2 and implications for human disease: role of alternative splicing
Show Less
1 Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA
2 Institute of Biomedical Science, Mackay Medical college, New Taipei city, Taiwan, ROC
Front. Biosci. (Landmark Ed) 2013, 18(2), 504–519; https://doi.org/10.2741/4117
Published: 1 January 2013
Abstract

Alternative splicing is an important mechanism for modulating gene function that accounts for a considerable proportion of proteomic complexity in higher eukaryotes. Alternative splicing is often tightly regulated in a cell-type- or developmental-stage- specific manner and can cause a single gene to have multiple functions. Human Tissue transglutaminase (TGM2) is a multifunctional enzyme with transglutaminase crosslinking (TGase), G protein signaling and kinase activities that are postulated to play a role in many disease states. TGM2 mRNA is regulated by alternative splicing, producing C-terminal truncated forms of TGM2 that are predicted to have distinct biochemical properties and biological functions. In this review, we will discuss how alternatively spliced forms of TGM2 could modulate its roles in cancer, neurodegeneration, inflammation and wound healing.

Keywords
Alternative Splicing
Transglutaminase
Cancer
Neurodegenerative
Wound Healing
Review
Share
Back to top